Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Cellectar presented Phase 2b CLOVER WaM subset data at the IWWM showing iopofosine I 131 achieved an 87.5% overall response rate, 79.2% major response rate, and 100% clinical benefit rate in 24 WM patients treated immediately after BTK inhibitor therapy. Median duration of response was 16.0 months with 19.1-month treatment-free survival, and treatment-emergent adverse events occurred in under 10% of patients despite 75% being BTKi refractory.
Key figures
- Drug Name
- iopofosine I 131
- Phase Of Trial
- Phase 2b
- Cbr
- 100%
- Mrr
- 79.2%
- Orr
- 87.5%
- Teae rate
- less than 10% of patients
- Subset size
- 24
- Median dor months
- 16
- Treatment free survival months
- 19.1
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.